ETORCAN-PG Tablets – Pregabalin 75 mg SR + Etoricoxib 60 mg

ETORCAN-PG Tablets by Amcare Pharmaceuticals contain a fixed-dose combination of Pregabalin 75 mg in sustained-release form and Etoricoxib 60 mg. The combination is designed to address both neuropathic and inflammatory/nociceptive components of pain and may be considered by physicians for selected patients with chronic pain conditions, particularly chronic low back pain with a neuropathic component. Clinical studies of this specific 75 mg pregabalin prolonged-release + 60 mg etoricoxib combination have reported improvements in pain and functional outcomes in such patients.

Composition of ETORCAN-PG Tablets

Dosage form: Uncoated bilayered tablet
Strength: Pregabalin 75 mg SR + Etoricoxib 60 mg
Pack size: 10 × 10 Tablets
Route: Oral
Category: Prescription medicine
Company: Amcare Pharmaceuticals

---

What are ETORCAN-PG Tablets Used For?

ETORCAN-PG combines two medicines with different pharmacological actions:

• Pregabalin SR – used for neuropathic pain and related conditions.
• Etoricoxib – a selective COX-2 inhibitor used for pain and inflammation.

The combination may be prescribed for selected patients where neuropathic and inflammatory/nociceptive pain mechanisms occur together.

A Phase III randomized study specifically evaluated pregabalin prolonged-release 75 mg + etoricoxib 60 mg in adults with chronic low back pain and reported greater improvements in pain and functional measures compared with etoricoxib alone.

A 2026 multicentre Phase IV study of the same fixed-dose combination also evaluated patients with chronic low back pain with a neuropathic component over eight weeks and reported improvements in pain and disability measures.

Potential clinical applications include:

• Chronic low back pain with a neuropathic component
• Mixed neuropathic and nociceptive pain, when judged appropriate by a physician
• Pain associated with musculoskeletal conditions where both pain mechanisms are present

ETORCAN-PG should not be promoted as a general-purpose painkiller. The combination should be used for an appropriate diagnosis and under medical supervision.

---

How Does ETORCAN-PG Work?

1. Pregabalin 75 mg Sustained Release

Pregabalin acts on the α2δ subunit of voltage-gated calcium channels in the nervous system. By reducing the release of certain excitatory neurotransmitters, it can reduce abnormal nerve signalling associated with neuropathic pain.

Pregabalin can cause dizziness and somnolence, and its prescribing information also warns about respiratory depression, peripheral edema and risks associated with abrupt discontinuation.

2. Etoricoxib 60 mg

Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin production involved in pain and inflammation.

Etoricoxib is used for conditions including osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, with the appropriate dose depending on the indication.

Combined action

The two ingredients therefore target different components of pain:

Pregabalin → neuropathic/nerve-related pain signalling
Etoricoxib → inflammatory/nociceptive pain

This dual approach is the rationale behind studying this fixed-dose combination in chronic low back pain with a neuropathic component.

---

Dosage & Administration

ETORCAN-PG should be taken only as directed by the prescribing physician.

The exact regimen should be individualized according to:

• Type and severity of pain
• Duration of symptoms
• Kidney function
• Age
• Other medicines being taken
• Response and tolerability

The 75 mg pregabalin sustained-release + 60 mg etoricoxib combination has been studied in an eight-week chronic low-back-pain clinical trial, but this does not mean that every patient should receive the medicine for eight weeks.

Important

• Swallow the tablet as directed by the physician.
• Do not crush or alter the sustained-release component unless specifically instructed.
• Do not take more than the prescribed dose.
• Do not discontinue pregabalin abruptly without medical advice.

Pregabalin treatment may require gradual dose reduction when discontinued because abrupt or rapid discontinuation can increase withdrawal symptoms and, in patients with seizure disorders, seizure risk.

---

Benefits / Therapeutic Role

1. Addresses Neuropathic Pain

Pregabalin targets abnormal nerve signalling associated with neuropathic pain.

2. Addresses Inflammatory Pain

Etoricoxib provides COX-2-selective anti-inflammatory and analgesic activity.

3. Dual-Mechanism Pain Management

The combination is designed to address different mechanisms contributing to chronic pain rather than relying on a single pharmacological pathway.

4. Clinical Evidence for the 75/60 Combination

A randomized Phase III study of pregabalin prolonged-release 75 mg plus etoricoxib 60 mg found statistically significant improvements in pain and functional outcomes compared with etoricoxib alone in adults with chronic low back pain.

---

Possible Side Effects

Because ETORCAN-PG contains two active medicines, adverse effects associated with either component may occur.

Pregabalin-related effects may include:

• Dizziness
• Sleepiness/drowsiness
• Headache
• Fatigue
• Peripheral edema
• Nausea
• Blurred vision
• Dry mouth
• Weight gain

Etoricoxib-related effects may include:

• Abdominal discomfort
• Indigestion
• Nausea
• Headache
• Dizziness
• Increased blood pressure
• Fluid retention/edema
• Changes in liver enzymes

Seek urgent medical attention for:

• Difficulty breathing
• Swelling of the face, lips, tongue or throat
• Severe skin rash or blistering
• Chest pain
• Sudden weakness or neurological symptoms
• Black stools or vomiting blood
• Severe swelling
• Marked reduction in urine output

---

Precautions & Warnings

1. Drowsiness and Dizziness

Pregabalin can cause dizziness and somnolence. Avoid driving or operating machinery until you know how the medicine affects you.

2. Respiratory Depression

Pregabalin can cause respiratory depression, particularly when combined with opioids or other CNS depressants, or in patients with underlying respiratory impairment.

3. Kidney Function

Pregabalin is substantially eliminated through the kidneys, so dosage adjustment may be necessary in patients with renal impairment.

Etoricoxib also requires caution in patients with impaired renal function. The cited etoricoxib product information contraindicates use when creatinine clearance is below 30 mL/min.

4. Cardiovascular Risk

Etoricoxib can increase cardiovascular risk, particularly with higher doses and longer exposure. The lowest effective dose for the shortest appropriate duration should be used.

5. Blood Pressure

Etoricoxib may cause or worsen hypertension and can cause fluid retention or edema. Blood pressure monitoring is particularly important in susceptible patients.

6. Gastrointestinal Risk

Although etoricoxib is COX-2 selective, gastrointestinal ulceration, bleeding and perforation can still occur. Risk may increase with concomitant aspirin or other NSAIDs.

---

Drug Interactions

Tell your doctor about all medicines and supplements you are taking.

Particular attention is required with:

• Opioid pain medicines
• Benzodiazepines and other CNS depressants
• Other sedating medicines
• Other NSAIDs
• Aspirin
• Warfarin and other anticoagulants
• ACE inhibitors
• Angiotensin-II receptor blockers
• Diuretics
• Lithium
• Methotrexate
• Digoxin
• Cyclosporine or tacrolimus

Etoricoxib can interact with anticoagulants and medicines affecting blood pressure and kidney function. Pregabalin can have additive CNS-depressant effects with opioids and other CNS depressants.

---

Pregnancy & Breastfeeding

ETORCAN-PG should not be used during pregnancy unless specifically determined appropriate by a qualified physician.

Etoricoxib is contraindicated during pregnancy in the cited product information. Pregabalin prescribing information also contains pregnancy-related fetal-risk warnings.

Breastfeeding should be discussed with the prescribing physician before treatment.

---

Driving & Operating Machinery

ETORCAN-PG may cause:

• Dizziness
• Drowsiness
• Somnolence
• Blurred vision

Patients should avoid driving or operating machinery if these effects occur.

---

Storage

Store ETORCAN-PG Tablets:

• In a cool, dry place
• Away from direct sunlight
• Protected from excessive moisture
• Out of reach of children

Always follow the storage instructions printed on the approved product packaging.

---

Key Product Features

---

Why Choose ETORCAN-PG by Amcare Pharmaceuticals?

ETORCAN-PG combines Pregabalin 75 mg sustained release with Etoricoxib 60 mg in a bilayered tablet formulation.

The formulation is designed around complementary mechanisms of pain management, with pregabalin targeting neuropathic pain signalling and etoricoxib providing COX-2-selective anti-inflammatory and analgesic activity.

The exact suitability of this combination should be determined by a healthcare professional based on the patient’s diagnosis and risk profile.